The National COVID-19 Clinical Evidence Taskforce (NCCET) provides clinical COVID-19 guidelines which are updated on a regular basis with the latest research. Where evidence is available recommendations are evidence based; consensus is also used. Clinicians should refer to NCCET Living Guidelines for the latest recommendations surrounding drug treatments for COVID-19.
Clinicians should also refer to the following NSW resources which have been produced to assist with the safe and appropriate use of COVID-19 therapeutics:
As of 22 August 2022, the following medicines are provisionally approved by the TGA (see
COVID-19 treatments: Provisional registrations for up to date information) and available in NSW for use in the management of COVID-19. The provisional approval pathway allows sponsors to apply for time-limited provisional registration on the Australian Register of Therapeutic Goods (ARTG). It provides access to certain promising new medicines where we assess that the benefit of early availability of the medicine outweighs the risk inherent in the fact that additional data are still required (see
Provisional approval pathway: prescription medicines for further information).
Refer to the relevant Product Information for the approved indication(s) and dosing regimens.
Where the proposed use of a medicine for COVID-19 is off-label or contrary to the approved indication or dosing regimens, standard procedures must be followed as per
PD2016_033 Approval Process of Medicines for Use in NSW Public Hospitals. Examples include:
Drug and therapeutics Advisory Community of Practice.
Dr Nigel Lyons, Deputy Secretary, Health System Strategy and Planning, NSW Ministry of Health.
24 August 2022.
communities of practice.